404 related articles for article (PubMed ID: 16918396)
1. Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade.
Wood MD; Scott C; Clarke K; Cato KJ; Patel N; Heath J; Worby A; Gordon L; Campbell L; Riley G; Davies CH; Gribble A; Jones DN
CNS Neurol Disord Drug Targets; 2006 Aug; 5(4):445-52. PubMed ID: 16918396
[TBL] [Abstract][Full Text] [Related]
2. Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies.
Stark AD; Jordan S; Allers KA; Bertekap RL; Chen R; Mistry Kannan T; Molski TF; Yocca FD; Sharp T; Kikuchi T; Burris KD
Psychopharmacology (Berl); 2007 Feb; 190(3):373-82. PubMed ID: 17242925
[TBL] [Abstract][Full Text] [Related]
3. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile.
Schmidt AW; Lebel LA; Howard HR; Zorn SH
Eur J Pharmacol; 2001 Aug; 425(3):197-201. PubMed ID: 11513838
[TBL] [Abstract][Full Text] [Related]
4. Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions.
Tarazi FI; Zhang K; Baldessarini RJ
Psychopharmacology (Berl); 2002 May; 161(3):263-70. PubMed ID: 12021829
[TBL] [Abstract][Full Text] [Related]
5. Long-term effects of JL 13, a potential atypical antipsychotic, on rat dopamine and serotonin receptor subtypes.
Moran-Gates T; Massari C; Graulich A; Liégeois JF; Tarazi FI
J Neurosci Res; 2006 Aug; 84(3):675-82. PubMed ID: 16810690
[TBL] [Abstract][Full Text] [Related]
6. Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5-HT)2A and DA D2 antagonism and 5-HT1A partial agonism.
Huang M; Panos JJ; Kwon S; Oyamada Y; Rajagopal L; Meltzer HY
J Neurochem; 2014 Mar; 128(6):938-49. PubMed ID: 24164459
[TBL] [Abstract][Full Text] [Related]
7. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
[TBL] [Abstract][Full Text] [Related]
8. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release.
Ichikawa J; Ishii H; Bonaccorso S; Fowler WL; O'Laughlin IA; Meltzer HY
J Neurochem; 2001 Mar; 76(5):1521-31. PubMed ID: 11238736
[TBL] [Abstract][Full Text] [Related]
9. Serotonin receptors: their key role in drugs to treat schizophrenia.
Meltzer HY; Li Z; Kaneda Y; Ichikawa J
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1159-72. PubMed ID: 14642974
[TBL] [Abstract][Full Text] [Related]
10. The role of serotonin receptors in the action of atypical antipsychotic drugs.
Meltzer HY; Massey BW
Curr Opin Pharmacol; 2011 Feb; 11(1):59-67. PubMed ID: 21420906
[TBL] [Abstract][Full Text] [Related]
11. 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex.
Rollema H; Lu Y; Schmidt AW; Sprouse JS; Zorn SH
Biol Psychiatry; 2000 Aug; 48(3):229-37. PubMed ID: 10924666
[TBL] [Abstract][Full Text] [Related]
12. Dopamine release induced by atypical antipsychotics in prefrontal cortex requires 5-HT(1A) receptors but not 5-HT(2A) receptors.
Bortolozzi A; Masana M; Díaz-Mataix L; Cortés R; Scorza MC; Gingrich JA; Toth M; Artigas F
Int J Neuropsychopharmacol; 2010 Nov; 13(10):1299-314. PubMed ID: 20158933
[TBL] [Abstract][Full Text] [Related]
13. Generalization of serotonin (5-HT)1A agonists and the antipsychotics, clozapine, ziprasidone and S16924, but not haloperidol, to the discriminative stimuli elicited by PD128,907 and 7-OH-DPAT.
Dekeyne A; Rivet JM; Gobert A; Millan MJ
Neuropharmacology; 2001 Jun; 40(7):899-910. PubMed ID: 11378160
[TBL] [Abstract][Full Text] [Related]
14. Atypical antipsychotics: matching receptor profile to individual patient's clinical profile.
Shayegan DK; Stahl SM
CNS Spectr; 2004 Oct; 9(10 Suppl 11):6-14. PubMed ID: 15475871
[TBL] [Abstract][Full Text] [Related]
15. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis.
Kuroki T; Nagao N; Nakahara T
Prog Brain Res; 2008; 172():199-212. PubMed ID: 18772034
[TBL] [Abstract][Full Text] [Related]
16. Stimulation by antipsychotic agents of mitogen-activated protein kinase (MAPK) coupled to cloned, human (h)serotonin (5-HT)(1A) receptors.
Cussac D; Duqueyroix D; Newman-Tancredi A; Millan MJ
Psychopharmacology (Berl); 2002 Jul; 162(2):168-77. PubMed ID: 12110994
[TBL] [Abstract][Full Text] [Related]
17. Differential profile of typical, atypical and third generation antipsychotics at human 5-HT7a receptors coupled to adenylyl cyclase: detection of agonist and inverse agonist properties.
Rauly-Lestienne I; Boutet-Robinet E; Ailhaud MC; Newman-Tancredi A; Cussac D
Naunyn Schmiedebergs Arch Pharmacol; 2007 Oct; 376(1-2):93-105. PubMed ID: 17786406
[TBL] [Abstract][Full Text] [Related]
18. Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats.
Oyamada Y; Horiguchi M; Rajagopal L; Miyauchi M; Meltzer HY
Behav Brain Res; 2015 May; 285():165-75. PubMed ID: 25448429
[TBL] [Abstract][Full Text] [Related]
19. Unraveling monoamine receptors involved in the action of typical and atypical antipsychotics on glutamatergic and serotonergic transmission in prefrontal cortex.
López-Gil X; Artigas F; Adell A
Curr Pharm Des; 2010; 16(5):502-15. PubMed ID: 19909228
[TBL] [Abstract][Full Text] [Related]
20. Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine.
Bymaster FP; Falcone JF; Bauzon D; Kennedy JS; Schenck K; DeLapp NW; Cohen ML
Eur J Pharmacol; 2001 Nov; 430(2-3):341-9. PubMed ID: 11711053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
